摘要
目的 分析国内外一线核苷类药物治疗慢性乙型肝炎相关文献,了解目前一线核苷类药物治疗慢性乙型肝炎领域的研究现状、前沿热点和趋势。方法 检索2019年至2023年中国知网、维普资讯、万方数据、Web of Science核心合集数据库和PubMed医学文献数据库核心合集,纳入国内文献1 239篇、国外文献967篇,采用NoteExpress和Vosviewer软件进行文献可视化分析,绘制可视化知识图谱。结果 国内高频关键词有肝硬化、纤维化、肝细胞癌等,国外高频关键词有hepatocellular carcinoma、HBsAg、cirrhosis等。结论 国内研究着重于肝病进展及现有治疗方案的优化,合作网络相对集中;国外研究则关注于风险预测模型和长期疗效,合作网络呈多中心化。
Objective To analyze the current research status,frontier hotspots,and trends in the field of first-line nucleoside drugs therapy for chronic hepatitis B by reviewing relevant literature from China and abroad.Methods A comprehensive literature search was conducted in the core collections of Chinese databases(CNKI,VIP,Wanfang Data)and international databases(Web of Science Core Collection,PubMed)for articles published between 2019 and 2023 to collect 1239 Chinese literature and 967 international literature.NoteExpress and Vosviewer software were employed to perform visual analysis and generate knowledge maps.Results The most frequently used keywords in Chinese literature were“liver cirrhosis”,“fibrosis”and“hepatocellular carcinoma”,while in international literature,the terms“hepatocellular carcinoma”,“HBsAg”and“cirrhosis”predominated.Conclusion Research within China primarily targets at the progression of liver disease and the optimization of existing treatment options,featuring a cohesive network of collaboration.In contrast,international studies emphasize the development of risk prediction models and the assessment of long-term treatment efficacy,featuring a decentralized network of cooperation.
作者
曹思远
赵甫文
杨佳丽
李孟菲
毛艳琦
杨周雨
张蕾
CAO Siyuan;ZHAO Fuwen;YANG Jiali;LI Mengfei;MAO Yanqi;YANG Zhouyu;ZHANG Lei(Binzhou Medical University,Yantai 264003,Shandong,P.R.China;Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,Shandong,P.R.China)
出处
《滨州医学院学报》
2024年第5期409-413,共5页
Journal of Binzhou Medical University
基金
国家级大学生创新创业训练计划(202310440240)。
关键词
慢性乙型肝炎
核苷类药物
文献计量学
可视化
chronic hepatitis B
nucleoside drug
literature metrology
visualization